Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported open-market sales of an aggregate 524,998 shares of common stock in late February and early March 2026 under a Rule 10b5-1 trading plan adopted on August 11, 2025. The shares were sold in multiple transactions at weighted average prices, with sale prices ranging from $15.11 to $16.23 per share. Following these transactions, Robins directly holds 1,934,247 shares of Adaptive Biotechnologies common stock.
ADPT reported Form 144 notice showing proposed sales of Common Stock by Harlan Robins. The filing lists multiple dispositions with trade dates and amounts, including 10,000 shares on 01/06/2026 and 2,395 shares on 02/02/2026.
The filing also records awards acquired as compensation (Restricted Stock Units) on 03/06/2023. The entries show per‑trade counts and dollar values for recent sales; timing and sale method details appear in the transaction lines.
Adaptive Biotechnologies insider sale reported: Chad M. Robins reported multiple sales of Common Stock under Rule 144, with transactions dated between 01/05/2026 and 03/03/2026. The reported lots include individual sales such as 41,666 shares, 99,225 shares, 116,334 shares, and others, each with an accompanying cash amount in USD. The filings list broker details and aggregate per‑lot proceeds; timing and direction are sales as reported.
ADPT Form 144 notice lists proposed sales of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing shows a proposed sale dated 03/03/2026 tied to an exercise of stock options for 1,037,487 shares and earlier restricted stock units dated 03/04/2022 for 169,174 shares. The securities are listed on NASDAQ.
Harlan Robins reported multiple sales of Common Stock under Form 144, and lists restricted shares acquired as compensation.
The filing shows securities to be sold include 10,000 Common Stock shares acquired as Restricted Stock Units on 03/06/2023 as compensation. The sale activity includes multiple disposals on 12/03/2025, 12/04/2025, 01/06/2026, and early February–March 2026, including transactions of 27,212 shares on 12/03/2025 and 32,273 shares on 02/02/2026.
Adaptiiv, Inc. (ADPT) reporting person Chad M. Robins submitted Form 144 to sell common stock. The filing lists multiple proposed sales on several dates with individual lots shown by share count and proceeds. Examples include sales of 99,225 shares on 02/27/2026 and 41,666 shares on 01/05/2026.
Adaptive Biotechnologies (ADPT) insider Chad M. Robins reported multiple proposed sales of Common Stock under Rule 144. The excerpt lists repeated dispositions of 41,666 shares on 11/26/2025, 12/01/2025, 01/05/2026 and 02/02/2026, plus a 35,736-share entry on 11/26/2025. Each row shows a gross sale amount in dollars alongside the share counts.
Adaptive Biotechnologies reported strong 2025 growth driven by its MRD business. Revenue reached $277.0 million, up from $179.0 million in 2024, with MRD revenue of $212.3 million, a 46% increase. clonoSEQ test volume rose to 105,587 tests, up 39% year-over-year.
Net cash used in operations fell to $46.0 million from $95.2 million, while cash, cash equivalents and marketable securities totaled $227.2 million as of December 31, 2025. The company also highlighted growing payor coverage, extensive MRD use in over 180 active trials and new IM data and partnerships, including non‑exclusive agreements with Pfizer.
Adaptive Biotechnologies Chief Financial Officer Kyle Piskel reported routine share transactions under a pre-set trading plan. On February 4, 2026, he exercised 2,145 stock options at $12.14 per share and acquired the same number of common shares.
That same day, he sold 2,145 common shares at $18.46 per share under a Rule 10b5-1 trading plan adopted on August 28, 2025. Following these transactions, he directly owned 216,637 shares of common stock and 2,146 stock options. The options originally vested 25% on March 4, 2023, with the remainder vesting monthly thereafter.